Investment opportunities in cannabinoid medicine R&D

Investors

CRDG connects investors with innovative companies in the cannabinoid medicine sector. Our members are developing new therapies and solutions in a rapidly growing field, with potential to impact healthcare globally.

Why Invest in CRDG Member Companies?

Investing in CRDG member companies offers access to early-stage innovations in biotech, pharmaceuticals, and therapeutics. We help connect investors with companies that align with their goals.

Research and Innovation
Our member companies focus on cutting-edge research in cannabinoid medicine.

Market Growth
The cannabinoid medicine market is expanding, driven by increasing demand for new treatments.

Expert Support
Our co-chairs, George Freeman MP and Professor Trevor Jones CBE FMed Sci, provide CRDG with valuable advice on engaging with key investors, academia and industry leaders. Their expertise and connections offer a solid foundation for growth in the cannabinoid medicine sector.

Success Stories

The success of GW Pharmaceuticals, acquired for $7.2 billion by Jazz Pharmaceuticals, underscores the growth potential in this field. In the first year after the acquisition, Jazz reported over $658 million in sales from Epidiolex, GW’s flagship cannabinoid-based therapy.

Several CRDG member companies have already made significant progress, from securing funding to advancing clinical trials. Their success highlights the potential for growth and impact in this sector.